Exosomics, Siena, Italy, has implemented the NanoAnalyzer instrument from NanoFCM, Nottingham, UK, to offer sophisticated contract research and measurement services worldwide.
Dimitri Aubert, PhD, NanoFCM.
In this strategic partnership, Exosomics becomes NanoFCM’s approved service supplier for nanoflow cytometry measurements. Such measurements can be performed as standalone or coupled to solutions provided by Exosomics.
“Thanks to their NanoAnalyzer, Exosomics will be able to supply the widest range of nanoflow cytometry measurements, which are in high demand across Europe and the rest of the world,” says Dimitri Aubert, PhD, managing director of NanoFCM. “We are delighted to recommend Exosomics to our close collaborators wishing to access the NanoAnalyzer platform on a punctual basis or as part of a wider range of services that would accelerate internal research and development capabilities.”
Antonio Chiesi, MD, Exosomics.
“We believe that by implementing the nanoflow cytometry platform we are once more leading the extracellular vesicles research field, and we can offer the widest range of services to biotech/pharma and academic groups,” says Antonio Chiesi, MD, chief executive officer of Exosomics. “This instrument will also allow us to further develop our own liquid biopsy pipeline, which requires the highest level of accuracy and reproducibility.”
The NanoAnalyzer is designed for research use only. It is not intended for diagnostic procedures.
For more information, visit Exosomics and NanoFCM.
